H-1B Filings
282
Major sponsor. DOL labor condition applications on file.
Regeneron Pharmaceuticals, Inc. in NY (Professional & Technical Services) is a sponsorship-and-safety profile: 282 H-1B LCAs plus an employer-specific OSHA injury record, with no WARN notices in this corpus.
Regeneron Pharmaceuticals, Inc. (NY): · 282 H-1B LCAs at a $165,000 disclosed median · OSHA Grade F (DART 0.50)
According to DOL OFLC H-1B disclosures, OSHA ITA injury logs, and state WARN Act notices, Regeneron Pharmaceuticals, Inc. in NY carries 282 H-1B wage filings on record, a $165,000 median wage across 170 disclosed-wage positions (above the $124,488 national median), a weak F OSHA safety grade and no WARN layoff notices on file. Every figure is a federal filing, not an estimate; see methodology for coverage limits.
The record at a glance
Compared with the rest of PlainEmployers' federal employer corpus, H-1B filing volume ranks #148 of 51,370 sponsors in this corpus (about the 100th percentile), and disclosed median wage sits at the 77th percentile of 272,125 credible H-1B wage rows.
Figures above come from DOL H-1B LCAs and this employer's OSHA injury log; no WARN notices are on file here.
A weighted composite of DOL H-1B sponsorship and pay, OSHA establishment injury records, and WARN Act layoff notices, not culture, benefits, or "is this a good place to work." Missing tracks drop out and their weight redistributes so sparse records are not silently deflated.
Weights (redistributed when a track is N/A): Sponsorship scale (H-1B volume) 15% · Disclosed pay (H-1B wage percentile) 25% · Workplace safety (OSHA DART percentile) 35% · Layoff stability (WARN percentile) 25%. Sources: DOL OFLC · OSHA ITA · state WARN filings.
H-1B Filings
282
Major sponsor. DOL labor condition applications on file.
Median H-1B Salary
$165,000
Above national median. Across 170 disclosed positions
OSHA Safety Grade
Grade F · DART 0.50
Riskier than industry average. vs 0.27 same 2-digit NAICS sector (OSHA ITA 2022–2023, hours-weighted)
Where Regeneron Pharmaceuticals, Inc.'s H-1B wage sits nationally
Median disclosed wage vs. all US employers with H-1B filings
$165,000 Top 23% higher than 77% of 272,125 US employers
Each bar is a $20K-wide band; taller bars hold more US employers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source DOL Office of Foreign Labor Certification, H-1B Disclosure Data · August 2026
Filing-count-weighted median across this employer's own disclosed H-1B positions (-0.3% year over year), not a company-wide raise, and not adjusted for role mix changes between years.
| Field | Value | Source |
|---|---|---|
| Employer Name | Regeneron Pharmaceuticals, Inc. | DOL OFLC / OSHA |
| Industry | Professional & Technical Services | NAICS / DOL |
| State | NY | U.S. Federal Records |
| H-1B Filings | 282 | DOL OFLC LCA Disclosure |
| H-1B Median Salary | $165,000 | DOL OFLC LCA Disclosure |
| OSHA Safety Grade | F | OSHA ITA |
| OSHA DART Rate | 0.50 | OSHA ITA Establishment Records |
| Tracks not on file | WARN notices | Empty by design, not estimated |
Regeneron Pharmaceuticals, Inc.'s values above reflect the most recent DOL Labor Condition Applications, OSHA Injury Tracking Application records on file for this employer in NY (Professional & Technical Services). In this corpus, H-1B filing volume ranks #148 of 51,370 sponsors in this corpus (about the 100th percentile); disclosed median wage sits at the 77th percentile of 272,125 credible H-1B wage rows; OSHA DART rate is safer than roughly 59% of 214,554 employers with an establishment injury record.
| Job Title | Median |
|---|---|
| Exec Medical Director Clinical Sciences | $450,440 |
| Sr Medical Director Clinical Sciences | $410,000 |
| Sr Medical Director Medical Affairs | $380,000 |
| Executive Director Financial Planning & Analysis | $316,811 |
| Dir Global Patient Safety Sciences | $309,765 |
| Director Pathology | $304,783 |
| Director Medical Affairs | $293,550 |
| Associate Medical Director Clinical Sciences | $290,700 |
| Associate Director Pathology | $281,128 |
| Dir Statistical Programming | $276,292 |
| Director IT Operations Management | $263,260 |
| Dir IT Data Management | $251,771 |
| Director Product Management | $251,447 |
| Director IT Solutions Architecture | $249,874 |
| Associate Director Biostatistics | $234,675 |
| Assoc Dir Product Management | $229,190 |
| Assoc Dir Health Economics & Outcomes Research | $226,107 |
| Assoc Dir Biostatistics | $225,568 |
| Associate Director Imaging | $225,000 |
| Associate Director Clinical Sciences | $222,248 |
| Associate Director, Pharmacoepidemiology | $222,246 |
| Assoc Dir Service Delivery Management | $222,025 |
| Associate Director CMC Regulatory Affairs | $220,000 |
| Associate Director Product Management | $220,000 |
| Associate Director Research Program Management | $219,621 |
| Assoc Dir Statistical Programming | $218,946 |
| Associate Director Data Engineering | $217,032 |
| Senior Manager IT Applications | $216,295 |
| Assoc Dir Statistical Programming | $215,736 |
| Assoc Dir IT Architect | $214,728 |
| Associate Director Product Management | $214,141 |
| Associate Director, Service Delivery Management | $210,191 |
| Associate Director CDM Program Lead | $208,590 |
| Assoc Dir IT Data Management | $207,466 |
| Sr Mgr Product Management | $205,499 |
| Product Manager | $205,000 |
| Senior Manager Biostatistics | $203,514 |
| Sr Principal Scientist-Assay Development | $202,299 |
| Assoc Dir Service Delivery Management | $201,888 |
| Sr Mgr Pharmacoepidemiology | $200,850 |
| Senior Principal Scientist-Process Development | $200,271 |
| Senior Manager Statistical Programming | $198,000 |
| Senior Manager Data Engineering | $196,964 |
| Associate Director, Research Program Management | $195,188 |
| Senior Staff Engineer | $192,298 |
| Principal IT Engineer | $191,001 |
| Senior Manager, CDM Study Lead | $190,000 |
| Sr Manager CDM Study Lead | $190,000 |
| Sr Mgr Statistical Programming | $189,444 |
| Associate Director Global Patient Safety | $188,990 |
Regeneron Pharmaceuticals, Inc.'s most extreme placement is sponsorship scale: 282 H-1B LCAs rank higher than 100% of sponsors in this corpus (#148 of 51,370).
DART 0.5 tracks close to the 0.3 sector average (Grade F).
Disclosed pay runs high: $165,000 median beats 77% of credible wage rows and sits above the $124,488 national median.
No WARN Act mass-layoff notices are on file for Regeneron Pharmaceuticals, Inc. among Professional & Technical Services employers we track.
Regeneron Pharmaceuticals, Inc.'s DART rate (days away/restricted/transferred per 100 FTE) vs the hours-weighted 2-digit NAICS sector average from OSHA ITA 2022–2023 (Professional & Technical Services).
Total reported injuries on file: 55.
Where Regeneron Pharmaceuticals, Inc. sits
Across the 199 Professional & Technical Services sponsors in this corpus with both an H-1B filing count and a credible disclosed-wage median, Regeneron Pharmaceuticals, Inc. files more petitions than 72% of them and discloses a higher median wage than 82%, the high-volume, above-median pay quadrant. Filing volume is hiring scale, not pay; the axes are independent DOL OFLC disclosures (282 filings · $165,000 median here).
Each muted dot is one professional & technical services peer from a filings-stratified sample of 41; the brand marker is Regeneron Pharmaceuticals, Inc.. Source: DOL Office of Foreign Labor Certification H-1B LCA disclosures (credible wages recomputed from per-position filings, excluding parse errors above $500k).
Regeneron Pharmaceuticals, Inc.'s nearest H-1B-filing peers in Professional & Technical Services (home state NY). Each card links to that employer's federal-records profile.
Two federal-records peer sets for Regeneron Pharmaceuticals, Inc., both outside NY so the neighborhoods are not the same-industry VsCard above.
Nearest nationwide sponsors outside NY (282 filings here).
Nearest injury-rate peers outside NY (DART 0.50 here).
Peers are nearest-neighbor matches on disclosed filing counts and OSHA ITA DART rates; employers with fewer than 100 H-1B filings or fewer than 10 reported injuries are excluded from the comparison corpus.
What to check before working with Regeneron Pharmaceuticals, Inc.
For Regeneron Pharmaceuticals, Inc., read sponsorship pay (282 H-1B LCAs, median $165,000) next to the OSHA safety grade (F).
Regeneron Pharmaceuticals, Inc.'s figures are legally filed public records (DOL, OSHA, state WARN), not reviews or vendor estimates; a missing row is not proof the underlying activity never happened.
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from OSHA and the DOL Wage and Hour Division. Consult a qualified professional before making decisions based on this data.
Among 272,125 credible H-1B wage rows in this corpus, Regeneron Pharmaceuticals, Inc.'s disclosed median of $165,000 sits at the 77th percentile (above the $124,488 national median). The chart above uses a COUNT-exact percentile (rows below this wage ÷ total), not an interpolated estimate.
Regeneron Pharmaceuticals, Inc. has 282 H-1B filings on record, ranking #148 of 51,370 sponsors in this corpus (about the 100th percentile by volume). Filing volume is a sponsorship signal, not a headcount or hiring-quality score.
Regeneron Pharmaceuticals, Inc. carries Grade F from its establishment injury record (55 injuries on file; DART 0.50). That DART rate is safer than roughly 59% of 214,554 employers with an injury record in this corpus. Grades compare DART against industry averages, see the Interpreting Safety Grades guide.
Related guides: How OSHA safety grades are calculated · Using H-1B wage filings in salary negotiation
Read our methodology - how this data is sourced, computed, and verified.
This profile is rendered directly from DOL H-1B disclosure filings and OSHA Injury Tracking Application records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.